“Pharmaceutical Contract Manufacturing market set to grow to $138bn by 2024” says new Visiongain report

19 August 2019
Pharma

Visiongain has launched a new pharma report Pharmaceutical Contract Manufacturing Market 2019-2029: Active Ingredient (API) and Finished Dose Formulation (FDF), Generic APIs, HPAPIs, Solid Dosages, Injectable Dosages.

The contract manufacturing sector is more mature than other sectors of the pharma outsourcing industry and has therefore grown more slowly in recent years. Additionally, external factors such as pharma industry M&A, blockbuster patent expiries and limited funding for pharma development programmes, resulting from the global economic crisis that began in 2008, have restrained growth in the market in the last five years. However, growth continues to be driven by the pharma industry’s need to cut development and manufacturing costs, with a view to improving profitability and allowing companies to focus on core competencies, such as drug discovery and development.

The lead analyst of the report commented "The technologies that will be in the greatest demand in this decade are those that provide flexibility and faster turnover times for pharma companies. Many CMOs are investing in single-use technologies for biopharma manufacturing, as this provides a lower-cost solution for producing biological drugs, through continuous manufacturing processes. Microreactors will offer similar advantages in API manufacturing and CMOs will become more interested in continuous processes which are quicker, lower cost, more flexible and allow lower volume production. Other in-demand technologies will include spray drying, which will provide a cheaper alternative to lyophilisation. Spray drying also has the additional advantage of offering continuous manufacturing, Visiongain notes."

Leading companies featured in the report include Boehringer Ingelheim BioXcellence, Catalent, DPx Holdings (formerly DSM and Patheon), Evonik Degussa, Famar, Fareva, Lonza, Mylan, Teva, Vetter Pharma and other companies.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Fill-Finish Manufacturing Market Report 2021-2031

Automation is a rising trend in the supply chain as a way to reduce time to market and enhance efficiency. Automation is appealing for a variety of reasons, the most important of which is that it reduces human contact and hence interference.

02 September 2021

Read

Visiongain Publishes Epilepsy Therapeutics Market Report 2021-2031

As governments in emerging countries are taking measures to improve healthcare, it is positively impacting the anti-epileptic drugs market growth.

24 August 2021

Read

Visiongain Publishes OTC Drugs & Dietary Supplements Market Report 2021-2031

From a long-term perspective, the rapid growth of the mid-class economy will enhance the demand for OTC products in emerging economies such as China, India and Brazil.

24 August 2021

Read

Visiongain Publishes Bowel Management Systems Market Report 2021-2031

Growing female population with faecal incontinence to fuel bowel management systems market growth through 2031.

17 August 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever